Fenofibrate, a PPARα agonist, decreases atrogenes and myostatin expression and improves arthritis-induced skeletal muscle atrophy
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Arthritis is a chronic inflammatory illness that induces cachexia, which has a direct impact on morbidity and mortality. Fenofibrate, a selective PPARα activator prescribed to treat human dyslipidemia, has been reported to decrease inflammation in rheumatoid arthritis patients. The aim of this study was to elucidate whether fenofibrate is able to ameliorate skeletal muscle wasting in adjuvant-induced arthritis, an experimental model of rheumatoid arthritis. On day 4 after adjuvant injection, control and arthritic rats were treated with 300 mg/kg fenofibrate until day 15, when all rats were euthanized. Fenofibrate decreased external signs of arthritis and liver TNFα and blocked arthritis-induced decreased in PPARα expression in the gastrocnemius muscle. Arthritis decreased gastrocnemius weight, which results from a decrease in cross-section area and myofiber size, whereas fenofibrate administration to arthritic rats attenuated the decrease in both gastrocnemius weight and fast myofiber size. Fenofibrate treatment prevented arthritis-induced increase in atrogin-1 and MuRF1 expression in the gastrocnemius. Neither arthritis nor fenofibrate administration modify Akt-FoxO3 signaling. Myostatin expression was not modified by arthritis, but fenofibrate decreased myostatin expression in the gastrocnemius of arthritic rats. Arthritis increased muscle expression of MyoD, PCNA, and myogenin in the rats treated with vehicle but not in those treated with fenofibrate. The results indicate that, in experimental arthritis, fenofibrate decreases skeletal muscle atrophy through inhibition of the ubiquitin-proteasome system and myostatin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression
Lecker, S. H., Jagoe, R. T., Gilbert, A., Gomes, M., Baracos, V., Bailey, J., Price, S. R., Mitch, W. E., & Goldberg, A. L. (2004) · The FASEB Journal · doi:10.1096/fj.03-0610com · Cited by 1,539 · cited 1×
“The muscle-specific E3 ubiquitin-ligating enzymes atrogin 1 and muscle RING finger 1 (MuRF1) play an important role in muscle atrophy and serve as early markers of skeletal muscle atrophy, aiding in the diagnosis of muscle disease (30).”
BackgroundKhovidhunkit, W., Kim, M.-S., Memon, R. A., Shigenaga, J. K., Moser, A. H., Feingold, K. R., & Grunfeld, C. (2004) · Journal of Lipid Research · doi:10.1194/jlr.r300019-jlr200 · Cited by 1,481 · cited 1×
“In the acute-phase response, adipose tissue lipolysis and reesterification of free fatty acid to triglycerides are increased, leading to an increase in serum triglyceride levels (28).”
Vega, R. B., Huss, J. M., & Kelly, D. P. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.5.1868-1876.2000 · Cited by 1,195 · cited 1×
“PGC-1 is also a coactivator of PPAR in the transcriptional control of mitochondrial fatty acid oxidation (56).”
BackgroundSandri, M., Lin, J., Handschin, C., Yang, W., Arany, Z. P., Lecker, S. H., Goldberg, A. L., & Spiegelman, B. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607795103 · Cited by 974 · cited 1×
“It has been reported that PPAR coactivator 1 (PGC-1) is an important factor in the skeletal muscle in delaying atrophy by inhibiting FoxO3-dependent transcription of atrogin-1 and MuRF1 (48).”
BackgroundPGC-1 promotes insulin resistance in liver through PPAR-α-dependent induction of TRB-3
Koo, S.-H., Satoh, H., Herzig, S., Lee, C.-H., Hedrick, S., Kulkarni, R., Evans, R. M., Olefsky, J., & Montminy, M. (2004) · Nature Medicine · doi:10.1038/nm1044 · Cited by 550
Suppression of body fat accumulation in myostatin-deficient mice
McPherron, A. C., & Lee, S.-J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0213562 · Cited by 505 · cited 1×
“In addition, myostatin-deficient mice exhibit markedly increased muscle mass composed mainly of fast fibers (38).”
BackgroundMuscle Atrophy and Hypertrophy Signaling in Patients with Chronic Obstructive Pulmonary Disease
Doucet, M., Russell, A. P., Léger, B., Debigaré, R., Joanisse, D. R., Caron, M.-A., LeBlanc, P., & Maltais, F. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200605-704oc · Cited by 243 · cited 1×
“Similarly, it has been reported that in other chronic inflammatory illnesses such as chronic obstructive pulmonary disease, muscle atrophy is not due to a decrease in Akt signaling (16).”
BackgroundPeroxisome Proliferator-Activated Receptor Expression Is Reduced in Skeletal Muscle in COPD
Remels, A. H., Schrauwen, P., Broekhuizen, R., Willems, J., Kersten, S., Gosker, H. R., & Schols, A. M. (2007) · European Respiratory Journal · doi:10.1183/09031936.00144106 · Cited by 168 · cited 1×
“Similarly, in cachectic patients with chronic obstructive pulmonary disease, PPAR mRNA levels in skeletal muscle are decreased and correlated negatively with inflammatory markers in plasma (47).”
BackgroundZheng, B., Ohkawa, S., Li, H., Roberts‐Wilson, T. K., & Price, S. R. (2010) · The FASEB Journal · doi:10.1096/fj.09-151480 · Cited by 145 · cited 11×
“The lack of modifications in Akt signaling in the gastrocnemius of arthritic rats is in accord with the increased expression of IGF-I and IGF-I receptor in the gastrocnemius of these rats (10).”
BackgroundInfluentialCastillero, E., Martín, A. I., López-Menduiña, M., Villanúa, M. A., & López-Calderón, A. (2009) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00388.2009 · Cited by 53
Self-citation
Cited by
Molecular and cellular mechanisms of skeletal muscle atrophy: an update
Fanzani, A., Conraads, V. M., Penna, F., & Martinet, W. (2012) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-012-0074-6 · Cited by 370
The role of exercise-induced myokines in regulating metabolism
Huh, J. Y. (2018) · Archives of Pharmacal Research · doi:10.1007/s12272-017-0994-y · Cited by 242
Kim, Y., Kim, C.-S., Joe, Y., Chung, H. T., Ha, T. Y., & Yu, R. (2018) · Journal of Medicinal Food · doi:10.1089/jmf.2017.4108 · Cited by 69
Biology and Therapeutic Applications of Peroxisome Proliferator- Activated Receptors
P. Menendez-Gutierrez, M., Roszer, T., & Ricote, M. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612799436669 · Cited by 62
Muscle wasting in collagen-induced arthritis and disuse atrophy
de Oliveira Nunes Teixeira, V., Filippin, L. I., Viacava, P. R., de Oliveira, P. G., & Xavier, R. M. (2013) · Experimental Biology and Medicine · doi:10.1177/1535370213505961 · Cited by 40
“Most of the fibers richer in glycogen contain the type 2 myosin heavy chain,28 but some type 1 fibers may also be in this group.29 Although this subject is rarely studied, Castillero et al.22 described a reduction in type 1 and type 2 myofibers in a rat model of adjuvant-induced arthritis, with a higher decrease in th…”
BackgroundMethodResultInfluential
Metadata
- Authors
- Castillero, E., Nieto-Bona, M. P., Fernández-Galaz, C., Martín, A. I., López-Menduiña, M., Granado, M., Villanúa, M. A., & López-Calderón, A.
- Venue
- American Journal of Physiology-Endocrinology and Metabolism
- Publisher
- American Physiological Society
- Published
- 2011-05
- Volume
- 300
- Issue
- 5
- Pages
- E790-E799
- ISSN
- 0193-1849 (ISSN-L)
- 1522-1555
- OpenAlex
- W2169944864
- Cited by
- 58
- References
- 10
- FWCI
- 2.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fenofibrate, a PPARα agonist, decreases atrogenes and myostatin expression and improves arthritis-induced skeletal muscle atrophy. https://app.cochat.ai/papers/10.1152/ajpendo.00590.2010
- The paper
- Castillero, E., Nieto-Bona, M. P., Fernández-Galaz, C., Martín, A. I., López-Menduiña, M., Granado, M., Villanúa, M. A., & López-Calderón, A. (2011). Fenofibrate, a PPARα agonist, decreases atrogenes and myostatin expression and improves arthritis-induced skeletal muscle atrophy. American Journal of Physiology-Endocrinology and Metabolism. https://doi.org/10.1152/ajpendo.00590.2010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.